European Association of Dermato Oncology (EADO) Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2019
NCT04074096
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

EADO - European Association of Dermato Oncology

Active Ingredients

Drugs in Phase 2 Trials (2)

binimetinib (mektovi) (1 trial)

encorafenib (braftovi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2